Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced its earnings results on Monday, November 25th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by ($0.03), Fidelity Earnings reports. The company had revenue of $43.29 million for the quarter, compared to the consensus estimate of $36.97 million. Arrowhead Pharmaceuticals had a return on equity of 32.30% and a net margin of 40.27%.
Shares of ARWR opened at $70.86 on Wednesday. The stock has a 50-day moving average of $50.95 and a 200-day moving average of $34.52. The company has a market cap of $6.44 billion, a PE ratio of 102.70 and a beta of 1.98. Arrowhead Pharmaceuticals has a one year low of $10.41 and a one year high of $73.72.
Several research analysts recently issued reports on the company. Chardan Capital reaffirmed a “buy” rating and set a $81.00 target price (up from $45.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, November 29th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $50.00 target price (up from $24.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 19th. S&P Equity Research reissued a “buy” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, November 26th. ValuEngine lowered Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, B. Riley reissued a “buy” rating and issued a $83.00 price objective (up from $59.00) on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, November 27th. Two analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $72.80.
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 66,645 shares of Arrowhead Pharmaceuticals stock in a transaction dated Tuesday, September 24th. The stock was sold at an average price of $28.20, for a total transaction of $1,879,389.00. Following the completion of the transaction, the chief executive officer now owns 2,146,153 shares in the company, valued at approximately $60,521,514.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Kenneth Allen Myszkowski sold 37,884 shares of Arrowhead Pharmaceuticals stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $40.85, for a total value of $1,547,561.40. Following the transaction, the chief financial officer now owns 351,420 shares of the company’s stock, valued at approximately $14,355,507. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 203,071 shares of company stock valued at $7,968,443. 4.80% of the stock is currently owned by company insiders.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Featured Story: Why are percentage gainers important?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.